Cabazitaxel + carboplatin in treatment of mCRPC

A newly published article in Lancet Oncology has suggested that “taxane–platinum combinations have a clinically beneficial role in advanced prostate cancer”. … READ MORE …

Statins and the treatment of mCRPC with chemotherapy

A report on the UroToday web site has addressed a presentation given this week at the ESMO 2018 Congress in Munich, Germany, that is relevant to the potential value of taking a statin while you are being treated for very late stage prostate cancer. … READ MORE …

FDA approves lower dose of cabazitaxel in treatment of mCRPC

Yesterday, in line with previously reported data, the US Food and Drug Administration (FDA) approved the used of a 20 mg/ml dose of cabazitaxel (Jevtana) in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Patient preference and type of chemotherapy for mCRPC

In another presentation from the ESMO meeting in  Madrid, Spain, Fizazi et al. presented data from the randomized CABA-DOC trial  exploring patients’ preferences for either docetaxel or cabazitaxel as a first-line form of chemotherapy. … READ MORE …

Differing chemotherapies and their effects in the treatment of mCRPC

The results of two recent, large clinical trials may have some impact on the clinical use of cabazitaxel (Jevtana) in the treatment of late-stage prostate cancer. … READ MORE …

Final data from the failed, Phase III, AFFINITY trial of curstirsen + cabazitaxel + prednisone

In August we had reported on an announcement by OncoGenex Pharmaceuticals that, in the Phase III AFFINITY trial, the combination of custirsen + cabazitaxel (Jevtana) + prednisone had no significant impact on overall survival of men with metastatic, castration-resistant prostate cancer (mCRPC) who had already received first-line chemotherapy by comparison with cabazitaxel + prednisone alone. … READ MORE …

NICE changes it’s tune about cabazitaxel

According to news reports this morning, the National Institute for Health and Care Excellence (NICE) in England has changed its tune about covering cabazitaxel (Jevtana) as a treatment for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ NORE …

Can TMPRSS2-ERG gene expression predict low response to taxane therapy?

Drugs like docetaxel and cabazitaxel (taxanes) are among the most active forms of treatment in the management of men with metastatic, castration-resistant prostate cancer (mCRPC), but they don’t work for everyone. … READ MORE …

NHS to stop covering cost of cabazitaxel for mCRPC as of November

As reported in a wide spectrum of media over the past few days (see here for example), on Friday last week the National Health Service announced that it would no longer cover the costs associated with use of cabazitaxel (Jevtana) in the treatment of metastatic, castration-resistant prostate cancer (mCRPC) through the UK’s Cancer Drugs Fund — effective as of November 1, 2015. … READ MORE …

Does cabazitaxel have targeted potential in late stage prostate cancer?

A research team working just down the street here in Philadelphia thinks cabazitaxel (Jevtana) may have expanded potential in treatment of some men with castration-resistant prostate cancer (CRPC). … READ MORE …

Factors in the sequencing of late-stage prostate cancer treatments

A paper in the International Journal of Cancer offers information on the sequencing of cabazitaxel (CAB) and abiraterone acetate (ABI) in men with metastatic, castration-resistant prostate cancer (mCRPC) who have already progressed after treatment with docetaxel. … READ MORE …

New data on new and newer drugs at the GU Cancers meeting

A whole host of new data on drugs like sipuleucel-T, enzalutamide, abiraterone, and others was available in the poster sessions at the Genitourinary Cancers Ssympisum in Orlando today. … READ MORE …

Brain metastasis, new drugs, and future treatment of mCRPC

A new article on the Medcape Oncology web site discusses progress in the treatment of metastatic, catsration-resistant prostate cancer (mCRPC) and the specific relationship between risk for brain metastasis and the extension of overall survival. … READ MORE …

Appropriate sequencing of treatments among men with advanced prostate cancer

Whether a man is initially diagnosed with metastatic prostate cancer or progresses to have metastatic disease over time (after failure of standard first-line therapies), sooner or later they are all going to need — in consultation with their doctors — to decide on “the best” way to manage their progressive disease through sequential or concurrent use of a number of recently approved agents (always assuming that cost and access are not determining factors). … READ MORE …

OncoGenex starts enrollment in new Phase III trial of custirsen

According to a media release from OncoGenex Pharmaceuticals earlier today, the company has started to enroll patients in a second, randomized, Phase III clinical trial of custirsen (OGX-011), this time in combination with second-line chemotherapy. … READ MORE …